THE STANDARD By
Dominic Raab |
January 28th 2021 at 00:00:00 GMT +0300
This is an extraordinary moment for all nations as we wrestle with huge, interlinked challenges, including the Covid-19 pandemic, climate change, economic uncertainty and a range of security threats.
To meet these challenges and come out stronger, we need to work together more closely. The UK has a unique offer for East Africa – and that is what I discussed during my visit to the region last week, meeting leaders in Kenya, Sudan and Ethiopia.
The first element of our offer is working together to tackle Covid-19. The UK has been at the forefront of global efforts to develop a vaccine and we used our influence with the World Bank to secure $12 billion of funding to get vaccines to developing countries. I saw this partnership in action at Kemri labs in Nairobi, where UK and Kenyan expertise is coming together to do vital testing on Covid vaccines, as well as vaccines for diseases like malaria, Rift Valley F
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low .
VALNEVAJanuary 25, 2021 GMT
Saint-Herblain (France), Sao Paulo, (Brazil), January 25, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 20201. The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 20192.
SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 2020
1. The collaboration falls within the framework of the $23.4 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2019
2.
Under the collaboration, Valneva will transfer its chikungunya vaccine technology to Instituto Butantan, who will develop, manufacture and commercialize the vaccine in LMICs. In addition, Instituto Butantan will provide certain clinical and Phase 4 observational studies that Valneva will use to meet regulatory requireme
The department of agriculture, land reform and rural development has asked owners of cattle, sheep and goats to vaccinate their animals against Rift Valley Fever (RVF).
Abstract
The epidemiology of Rift Valley fever virus (RVFV) and Crimean-Congo hemorrhagic fever virus (CCHFV) in Jordan is unknown. Our investigation showed 3% of 989 tested dairy cattle, sheep, and goats were RVFV seropositive and 14% were CCHFV seropositive. Ongoing surveillance is needed to assess risk to humans and protect public health.
Rift Valley fever (RVF) virus (RVFV) and Crimean-Congo hemorrhagic fever (CCHF) virus (CCHFV) are zoonotic arboviruses. RVFV has been causing sporadic outbreaks in East, West, and southern Africa; the Indian Ocean region; and the Arabian Peninsula (Saudi Arabia and Yemen) (
1). Although Jordan is considered an at-risk country, the disease has not been reported in Jordan (